Use of tryptanthrin compounds for immune potentiation
The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance the immune response of a subject to an antigen. Also provided are methods of administering an effective amount of a tryptanthrin to stimulate the immune response in a subject for the treatment of cancer. Further provided are methods of administering a tryptanthrin compounds as an immunotherapeutic in the treatment of infectious diseases.
1. An immunogenic pharmaceutical composition comprising an antigen and a tryptanthrin compound adjuvant in an amount effective to provide an enhanced immune response to the antigen relative to the response provided without the tryptanthrin compound adjuvant.
2. The composition of claim 1 , further comprising an aqueous carrier.
3. The composition of claim 1 , wherein the antigen is associated with a disease selected from the group consisting of cholera, plague, typhoid, hepatitis B infection, influenza, inactivated polio, rabies, measles, mumps, rubella, oral polio, yellow fever, tetanus, diphtheria, hemophilus influenzae b, meningococcus infection, tick borne encephalitis, SARS, HCV, HIV, and pneumococcus infection.
4. The composition of claim 1 , wherein the tryptanthrin compound enhances an immune response to the antigen and the immune response is the cellular production of one or more cytokines.
5. The composition of claim 1 , wherein the tryptanthrin compound is a compound of Formula I:
wherein
A, B, C, D, E, F, G, and H are independently selected from carbon and nitrogen, or A and B and/or C and D can be taken together to be nitrogen or sulfur;
R 1 , R 2 , R 3 , R 4 , R 8 , and R 10 are independently selected from the group consisting of hydrogen, halogen, loweralkyl, alkyl, substituted alkyl, cycloalkyl, heterocyclyl, alkylheterocyclyl, substituted heterocyclyl, substituted alkenyl, amino, (substituted alkyl)(alkyl)amino, imino, haloloweralkyl, hydroxy, alkoxy, substituted alkoxy, hydroxyalkylthio, nitro, alkylsulfonyl, N-alkylsulfonamide, arylalkyl, arylalkylaryl, arylaryl, aryloxy, arylamino, acylamino, acyloxyamino, alkylaminoacylamino, alkylaminosulfonylamino, alkylamino, alkenylamino, dialkylamino, alkoxyalkylamino, alkoxyalkylheterocyclyl, mercaptoalkoxyalkyl, cyano, formyl, —COOR 11 wherein R 11 is hydrogen, loweralkyl, aryl, heterocyclyl, monosaccharide or disaccharide, and —CONR 12 R 13 wherein R 12 and R 13 are independently selected from hydrogen, loweralkyl, aryl, heterocyclyl, saccharide, peptide and amino acid residues; or R 2 and R 3 taken together form a six membered aromatic ring;
R 7 and R 9 are independently selected from hydrogen, halogen, loweralkyl, haloloweralkyl, cycloalkyl, heterocyclyl, substituted heterocyclyl or heterocyclylalkyl; and
R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 , and R 10 are absent when the ring atom to which they would otherwise be bonded is sulfur or double-bonded nitrogen; or
a pharmaceutically acceptable salt thereof,
provided that R 1 , R 2 , R 3 , R 4 , R 7 , R 8 , R 9 , and R 10 are not all hydrogen when A, B, C, D, E, F, and H are carbon.
6. The composition of claim 5 ,
wherein
A, B, C, D, E, F, G, and H are independently selected from carbon and nitrogen;
R 1 , R 2 , R 3 , R 4 , R 8 and R 10 are independently selected from the group consisting of hydrogen, halogen, loweralkyl, alkyl, substituted alkyl, heterocyclyl, substituted heterocyclyl, substituted alkenyl, (substituted alkyl)(alkyl)amino, haloloweralkyl, hydroxy, alkoxy, substituted alkoxy, hydroxyalkylthio, nitro, N-alkylsulfonamide, cyano, —COOR 11 wherein R 11 is hydrogen, loweralkyl, aryl, heterocyclyl, monosaccharide or disaccharide, and —CONR 12 R 13 wherein R 12 and R 13 are independently selected from hydrogen, loweralkyl, aryl, heterocyclyl, saccharide, peptide and amino acid residues.
7. The composition of claim 1 , wherein the tryptanthrin compound is selected from the group consisting of
8-nitroindolo[2,1-b]quinazoline-6, 1-2-dione,
3,8-difluoroindolo[2,1-b]quinazoline-6,12-dione,
10-fluoroindolo[2,1-b]quinazoline-6,12-dione,
1,8-difluoroindolo[2,1-b]quinazoline-6,12-dione,
8-fluoro-1-methylindolo[2,1-b]quinazoline-6,12-dione,
8,10-difluoroindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-fluoro-8-iodoindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-chloro-8-iodoindolo[2,1-b]quinazoline-6,12-dione,
2,4-dibromo-1-fluoroindolo[2,1-b]quinazoline-6,12-dione,
8-chloro-2-iodoindolo[2,1-b]quinazoline-6,12-dione,
8-chloro-3-fluoroindolo[2,1-b]quinazoline-6,12-dione,
8-fluoro-4-hydroxyindolo[2,1-b]quinazoline-6,12-dione,
N-ethyl-4-(methyloxy)-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-8-carboxamide,
3-fluoro-8-[(trifluoromethyl)oxy]indolo[2,1-b]quinazoline-6,12-dione,
3-[(2-hydroxyethyl)thio]-8-[(trifluoromethyl)oxy]indolo[2,1-b]quinazoline-6,12-dione,
pyrido[2′,′:4,5]pyrimido[1,2-a]indole-5,11-dione,
9-fluoropyrido[2′,′:4,5]pyrimido[1,2-a]indole-5,11-dione,
9-bromopyrido[2′,′:4,5]pyrimido[1,2-a]indole-5,11-dione,
9-chloropyrido[2′,′:4,5]pyrimido[1,2-a]indole-5,11-dione,
9-iodopyrido[2′,′:4,5]pyrimido[1,2-a]indole-5,11-dione,
ethyl 5,11-dioxo-5,11-dihydropyrido[2′,′:4,5]pyrimido[1,2-a]indole-9-carboxylate,
N-octyl-5,11-dioxo-5,11-dihydropyrido[2′,′:4,5]pyrimido[1,2-a]indole-9-sulfonamide,
10-(trifluoromethyl)pyrido[2′,′:4,5]pyrimido[1,2-a]indole-5,11-dione,
(5E)-6-(5,11-dioxo-5,11-dihydropyrido[2′,′:4,5]pyrimido[1,2-a]indol-9-yl)hex-5-enyl acetate,
6-(5,11-dioxo-5,11-dihydropyrido[2′,′:4,5]pyrimido[1,2-a]indol-9-yl)hexyl dihydrogen phosphate, and
9-[(trifluoromethyl)oxy]pyrido[2′,′:4,5]pyrimido[1,2-a]indole-5,11-dione,
or a pharmaceutically acceptable salt thereof.